Review article · 2019 · Open access

iPS-Cell Technology and the Problem of Genetic Instability—Can It Ever Be Safe for Clinical Use?

Stephen W. Attwood, Michael J. Edel

Journal of Clinical Medicine, 8(3), 288 · Published 28 February 2019 · DOI 10.3390/jcm8030288

Open PDFView at the publisherCite this paper

In brief

“iPS-Cell Technology and the Problem of Genetic Instability—Can It Ever Be Safe for Clinical Use?” is a 2019 review article by Stephen W. Attwood and Michael J. Edel, published in Journal of Clinical Medicine. OpenAlex counts 107 citations as of 21 November 2026, which puts it in the top 1% of works published in 2019 by citations. It is open access under a CC BY licence: the full text is free to read at Journal of Clinical Medicine.

Citations
107
Most cited in
2020 (17)
Field-weighted impact
1.11
References
198
Authors
2

Abstract

The use of induced Pluripotent Stem Cells (iPSC) as a source of autologous tissues shows great promise in regenerative medicine. Nevertheless, several major challenges remain to be addressed before iPSC-derived cells can be used in therapy, and experience of their clinical use is extremely limited. In this review, the factors affecting the safe translation of iPSC to the clinic are considered, together with an account of efforts being made to overcome these issues. The review draws upon experiences with pluripotent stem-cell therapeutics, including clinical trials involving human embryonic stem cells and the widely transplanted mesenchymal stem cells. The discussion covers concerns relating to: (i) the reprogramming process; (ii) the detection and removal of incompletely differentiated and pluripotent cells from the resulting medicinal products; and (iii) genomic and epigenetic changes, and the evolutionary and selective processes occurring during culture expansion, associated with production of iPSC-therapeutics. In addition, (iv) methods for the practical culture-at-scale and standardization required for routine clinical use are considered. Finally, (v) the potential of iPSC in the treatment of human disease is evaluated in the light of what is known about the reprogramming process, the behavior of cells in culture, and the performance of iPSC in pre-clinical studies.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Attwood, S. W., & Edel, M. J. (2019). iPS-Cell Technology and the Problem of Genetic Instability—Can It Ever Be Safe for Clinical Use? Journal of Clinical Medicine, 8(3), 288. https://doi.org/10.3390/jcm8030288

MLA 9

Attwood, Stephen W., and Michael J. Edel. “iPS-Cell Technology and the Problem of Genetic Instability—Can It Ever Be Safe for Clinical Use?” Journal of Clinical Medicine, vol. 8, no. 3, 2019, p. 288. https://doi.org/10.3390/jcm8030288.

Chicago

Attwood, Stephen W. and Michael J. Edel. 2019. “iPS-Cell Technology and the Problem of Genetic Instability—Can It Ever Be Safe for Clinical Use?” Journal of Clinical Medicine 8 (3): 288. https://doi.org/10.3390/jcm8030288.

Harvard

Attwood, S. W. and Edel, M. J. (2019) ‘iPS-Cell Technology and the Problem of Genetic Instability—Can It Ever Be Safe for Clinical Use?’, Journal of Clinical Medicine, 8(3), p. 288. doi:10.3390/jcm8030288.

IEEE

S. W. Attwood and M. J. Edel, “iPS-Cell Technology and the Problem of Genetic Instability—Can It Ever Be Safe for Clinical Use?,” Journal of Clinical Medicine, vol. 8, no. 3, p. 288, 2019, doi: 10.3390/jcm8030288.

BibTeX

@article{attwood2019cell,
  title     = {{iPS-Cell Technology and the Problem of Genetic Instability—Can It Ever Be Safe for Clinical Use?}},
  author    = {Attwood, Stephen W. and Edel, Michael J.},
  journal   = {Journal of Clinical Medicine},
  year      = {2019},
  volume    = {8},
  number    = {3},
  pages     = {288},
  doi       = {10.3390/jcm8030288},
  url       = {https://doi.org/10.3390/jcm8030288}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
20191010
20201717
20211313
20221515
20231010
20241616
20251010
20261616

Its field-weighted citation impact is 1.11: it has been cited 1.11 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research

  • induced pluripotent stem cells
  • genomic instability
  • clinical translation
  • reprogramming
  • genomic changes
  • epigenetic modifications
  • standardization
  • human embryonic stem cells

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Attwood, S. W., & Edel, M. J. (2019). iPS-Cell Technology and the Problem of Genetic Instability—Can It Ever Be Safe for Clinical Use? Journal of Clinical Medicine, 8(3), 288. https://doi.org/10.3390/jcm8030288

How many times has this paper been cited?

107 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Journal of Clinical Medicine: sign in and open the PDF from this page.

Who wrote this paper?

Stephen W. Attwood, Michael J. Edel.

What is the DOI of this paper?

10.3390/jcm8030288, permanently at https://doi.org/10.3390/jcm8030288. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.